On December 29, 2025, Mereo BioPharma Group plc reported that its Phase 3 studies of setrusumab for osteogenesis imperfecta did not meet primary endpoints for reducing fracture rates, but showed significant improvements in bone mineral density compared to placebo. This event is neither significantly positive nor negative for the company from an investor perspective.